Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists Versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2023 Apr 18

PMID 37069844

Authors

Pei-An Liao

Sheng-Wei Pan

Chun-Yu Chen

Chung-Yeh Deng

Yaa-Hui Dong

Affiliations

Soon will be listed here.

Abstract

Background: The clinical guideline recommends use of long-acting β2 agonists/long-acting muscarinic antagonists (LABA/LAMA) or long-acting β2 agonists/inhaled corticosteroids (LABA/ICS) combination therapies for patients with severe chronic obstructive pulmonary disease (COPD). The fixed-dose combination (FDC) inhalers of LABA/LAMA and LABA/ICS were reimbursed in Taiwan in 2015 and in 2002, respectively. This study aimed to examine prescription patterns of new use of either FDC therapy in real-world practice.

Methods: We identified COPD patients who initiated LABA/LAMA FDC or LABA/ICS FDC between 2015 and 2018 from a population-based Taiwanese database with 2 million, randomly sampled beneficiaries enrolled in a single-payer health insurance system. We compared number of LABA/LAMA FDC and LABA/ICS FDC initiators in each calendar year, from different hospital accreditation levels, and cared for by different physician specialties. We also compared baseline patient characteristics between LABA/LAMA FDC and LABA/ICS FDC initiators.

Results: A total of 12,455 COPD patients who initiated LABA/LAMA FDC (n=4019) or LABA/ICS FDC (n=8436) were included. Number of LABA/LAMA FDC initiators increased apparently (n=336 in 2015 versus n=1436 in 2018), but number of LABA/ICS FDC initiators decreased obviously (n=2416 in 2015 versus n=1793 in 2018) over time. The preference of use of LABA/LAMA FDC varied across clinical environments. The proportions of LABA/LAMA FDC initiators were more than 30% in the setting of non-primary care clinics (eg, medical centers) and in the services of chest physicians; but were only less than 10% in primary care clinics and non-chest physicians' services (eg, family medicine physicians). LABA/LAMA FDC initiators appeared to be older, male, to have more comorbidities, and to utilize resources more frequently compared to LABA/ICS FDC initiators.

Conclusion: This real-world study found evident temporal trends, variations in healthcare provider, and differences in patient characteristics among COPD patients who initiated LABA/LAMA FDC or LABA/ICS FDC.

Citing Articles

Comparative cardiovascular safety of LABA/LAMA FDC versus LABA/ICS FDC in patients with chronic obstructive pulmonary disease: a population-based cohort study with a target trial emulation framework.

Chen C, Pan S, Hsu C, Liu J, Kumamaru H, Dong Y Respir Res. 2023; 24(1):239.

PMID: 37775734 PMC: 10543303. DOI: 10.1186/s12931-023-02545-9.

References

Moretz C, Sharpsten L, Bengtson L, Koep E, Le L, Tong J . Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2019; 14:1721-1737. PMC: 6681903. DOI: 10.2147/COPD.S204649. View

Austin P . Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009; 28(25):3083-107. PMC: 3472075. DOI: 10.1002/sim.3697. View

Horita N, Goto A, Shibata Y, Ota E, Nakashima K, Nagai K . Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017; 2:CD012066. PMC: 6464543. DOI: 10.1002/14651858.CD012066.pub2. View

Mamdani M, Sykora K, Li P, Normand S, Streiner D, Austin P . Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ. 2005; 330(7497):960-2. PMC: 556348. DOI: 10.1136/bmj.330.7497.960. View

Chen H, Sun J, Huang Q, Liu Y, Yuan M, Ma C . Inhaled Corticosteroids and the Pneumonia Risk in Patients With Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials. Front Pharmacol. 2021; 12:691621. PMC: 8275837. DOI: 10.3389/fphar.2021.691621. View

Lin L, Warren-Gash C, Smeeth L, Chen P . Data resource profile: the National Health Insurance Research Database (NHIRD). Epidemiol Health. 2019; 40:e2018062. PMC: 6367203. DOI: 10.4178/epih.e2018062. View

Parkin L, Khuu W, Stanbrook M, Tadrous M, Martins D, Gomes T . Trends in the utilisation of COPD therapeutic regimens before and after the introduction of LAMA/LABA combination products: A population-based study. Respir Med. 2018; 143:1-7. DOI: 10.1016/j.rmed.2018.08.001. View

Samp J, Joo M, Schumock G, Calip G, Pickard A, Lee T . Comparative Effectiveness of Long-Acting Beta -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease. Pharmacotherapy. 2017; 37(4):447-455. DOI: 10.1002/phar.1913. View

Bloom C, Elkin S, Quint J . Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016. Int J Chron Obstruct Pulmon Dis. 2019; 14:279-287. PMC: 6349076. DOI: 10.2147/COPD.S190086. View

10.

Gershon A, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T . Identifying individuals with physcian diagnosed COPD in health administrative databases. COPD. 2009; 6(5):388-94. DOI: 10.1080/15412550903140865. View

11.

Wang M, Lai J, Huang Y, Liou J, Cheng S, Lin C . Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β-Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting β-Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD A Propensity.... Chest. 2021; 160(4):1255-1270. DOI: 10.1016/j.chest.2021.05.025. View

12.

Sharif R, Cuevas C, Wang Y, Arora M, Sharma G . Guideline adherence in management of stable chronic obstructive pulmonary disease. Respir Med. 2013; 107(7):1046-52. DOI: 10.1016/j.rmed.2013.04.001. View

13.

Deyo R, Cherkin D, Ciol M . Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45(6):613-9. DOI: 10.1016/0895-4356(92)90133-8. View

14.

Lee S, Lee J, Yoon H, Park H, Kim T, Yoo K . Change in inhaled corticosteroid treatment and COPD exacerbations: an analysis of real-world data from the KOLD/KOCOSS cohorts. Respir Res. 2019; 20(1):62. PMC: 6437901. DOI: 10.1186/s12931-019-1029-7. View

15.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

16.

Quint J, Montonen J, Esposito D, He X, Koerner L, Wallace L . Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database. Adv Ther. 2021; 38(5):2249-2270. PMC: 8107175. DOI: 10.1007/s12325-021-01646-5. View

17.

Dong Y, Chang C, Wu F, Shen L, Calverley P, Lofdahl C . Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials. Chest. 2014; 145(6):1286-1297. DOI: 10.1378/chest.13-2137. View

18.

Mannino D, Siddall J, Small M, Haq A, Stiegler M, Bogart M . Treatment Patterns for Chronic Obstructive Pulmonary Disease (COPD) in the United States: Results from an Observational Cross-Sectional Physician and Patient Survey. Int J Chron Obstruct Pulmon Dis. 2022; 17:749-761. PMC: 8995154. DOI: 10.2147/COPD.S340794. View

19.

Gruffydd-Jones K, Brusselle G, Jones R, Miravitlles M, Baldwin M, Stewart R . Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: in UK primary care: a real-world, retrospective, observational. NPJ Prim Care Respir Med. 2017; 26:16002. PMC: 5375386. DOI: 10.1038/npjpcrm.2016.2. View

20.

Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43(11):1130-9. DOI: 10.1097/01.mlr.0000182534.19832.83. View